Literature DB >> 31671171

Human Hepegivirus-1: Innocent Traveler, Helpful Symbiote, or Insidious Pathogen?

Abraham J Kandathil1, Ashwin Balagopal1.   

Abstract

Entities:  

Year:  2020        PMID： 31671171      PMCID： PMC7768746          DOI： 10.1093/cid/ciz947

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  33 in total

1.  Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential.

Authors:  B G Pavlova; R Heinz; U Selim; H Tüchler; E Pittermann; G Eder
Journal:  J Med Virol       Date:  1999-04       Impact factor: 2.327

2.  GB virus C infection and non-Hodgkin lymphoma: important to know but the jury is out.

Authors:  Jack T Stapleton; Kathryn Chaloner
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

3.  Prevalence of hepatitis G viremia among healthy subjects, individuals with liver disease, and persons at risk for parenteral transmission.

Authors:  H H Feucht; B Zöllner; S Polywka; B Knödler; M Schröter; H Nolte; R Laufs
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

4.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

5.  Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study.

Authors:  D Ernst; M Greer; R Akmatova; S Pischke; H Wedemeyer; H Heiken; H L Tillmann; R E Schmidt; M Stoll
Journal:  HIV Med       Date:  2013-10-07       Impact factor: 3.180

6.  GBV-C infection and risk of NHL among U.S. adults.

Authors:  Cindy M Chang; Jack T Stapleton; Donna Klinzman; James H McLinden; Mark P Purdue; Hormuzd A Katki; Eric A Engels
Journal:  Cancer Res       Date:  2014-08-12       Impact factor: 12.701

7.  Persistence and clinical significance of hepatitis G virus infections in injecting drug users.

Authors:  D L Thomas; Y Nakatsuji; J W Shih; H J Alter; K E Nelson; J A Astemborski; C M Lyles; D Vlahov
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

8.  The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic Cooperative Oncology Group Study.

Authors:  E Giannoulis; T Economopoulos; K Mandraveli; K Giannoulis; C Nikolaides; E Zervou; E Papageorgiou; D Zoulas; A Tourkantonis; G Giannopoulos; G Fountzilas
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

9.  Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors.

Authors:  Adnan Y Chowdhury; John E Tavis; Sarah L George
Journal:  Virology       Date:  2014-04-24       Impact factor: 3.616

10.  GBV-C viremia and clinical events in advanced HIV infection.

Authors:  Harleen Sahni; Katherine Kirkwood; Tassos C Kyriakides; Jack Stapleton; Sheldon T Brown; Mark Holodniy
Journal:  J Med Virol       Date:  2013-11-19       Impact factor: 2.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.